Study #2025-0369
VIKTORIA-2: A randomized, open-label, phase 3 study of Fulvestrant and CDK4/6 inhibitors with or without Gedatolisib as first-line treatment in patients with HR-positive and HER2-negative advanced breast cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant, Arm B: Palbociclib or Ribociclib + Fulvestrant
Description
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer
Study phase:
Phase III
Physician name:
Rachel Layman
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.